induction

Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.

...en two or more medications for the same enzyme, or induction (increase) of a particular CYP enzymes activity in response to a particular medication. In the former scenario, blood concentrations and the risk of side effects can rise to perilous levels; in the latter, concentrations can decline to the point tha...

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

...a, its conditions of onset ( e.g. during leukemia induction therapy, which may be associated with a pre-existing infection), and fever monitoring, associated with pathogen identification in only 25-30% of these cases, leading to emergency requirements in some instances. Based on solid clinical analysis and a ...

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

...ed kinases,resulting in inhibition of cell growth, induction of apoptosis, anddecreased matrix metalloproteinase and vascular endothelial growthfactor production. In vitro, ERBITUX can mediate antibody-dependentcellular cytotoxicity (ADCC) against certain human tumor types.While the mechanism of ERBITUX' anti-...

Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression

...inor damage toarresting cell cycle progression and induction of apoptotic celldeath. Inactivation of the tumor suppressing function of p53 is oneof the most frequent genetic alterations in human cancer, and closeto half of all human tumors carry p53 gene mutations within theircells. As a transcription factor, ...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

... newly diagnosed multiple myeloma (MM)patients. As induction therapy prior to stem cell transplantation(SCT), t...ubstantiallystronger than those of a commonly used induction chemotherapyregimen vincristine, adriamycin and dexamethasone (VAD), whichserved as the comparative ...

ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

...lting indepletion of energy supply to the cell and induction of apoptosis(programmed cell death). Increase in intra-cellular Reactive OxygenSpecies enhances this effect on mitochondrial functions andconsequently the activation of the signal transduction pathwayleading to apoptosis. In addition, darinaparsin in...

Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company

...disease itself. Preliminary data from the 24-week induction phase show thatCellCept achieved results that are equivalent to those achievedwith intravenous Cyclophosphamide (IVC), a chemotherapy which hasbeen used to treat patients with lupus kidney disease (lupusnephritis) since the 1970s. However, while IVC ...

Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis

...ard of care, forinducing treatment response in the induction phase of patientssuffering from lupus nephritis. A...response in this disease. Theresults relate to the induction phase of this study, which wasdesigned to measure treatment response in patients after 24 weeksof in...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis

...multiple sclerosis patientsresulted in the in vivo induction of CD8+ cytotoxic T-cells andCD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction ofanti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypicCD4+CD25+FoxP3 positive Tregs is ...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

...06-AngQb has been shown to reduce bloodpressure by induction of antibodies that bind angiotensin II.Thereby, binding of angiotensin II to its receptors and subsequentnarrowing of blood vessels should be decreased. The RAS has alreadybeen successfully targeted by three major classes ofantihypertensive drugs on ...

Remicade Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation

...on administered every6 weeks, following a standard induction regimen that requirestreatment at weeks 0, 2 and 6. Centocor discovered REMICADE and has exclusive marketing rightsto the product in the United States. Schering-Plough markets REMICADE in all countries outside of theUnited States, except in Japan a...

Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting

...istered in a 30-60 minuteinfusion on day 1 (second induction allowed) and provided theoption for an additional ...lve (20%)patients died within 30 days of receiving induction treatment. Themajority of early death was in patients with secondary AML and wasdue to disease progr...

Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

...rolled mechanism." "These new data suggest that induction of an expandingpopulation of TCR-reactive, Foxp3+ Tregs by NeuroVax(TM) may beable to exert broad and potent immunomodulatory effects onpathogenic T cells," said Dr. Joseph O'Neill, President and CEO ofOrchestra Therapeutics, Inc. "The indication tha...

Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting

...multiple sclerosis patientsresulted in the in vivo induction of CD8+ cytotoxic T-cells andCD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction ofanti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypicCD4+CD25+FoxP3 positive Tregs is ...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

... results of a Phase IIneoadjuvant study evaluating induction ERBITUX plus chemotherapyfollowed by ERBITUX plus ...ed kinases,resulting in inhibition of cell growth, induction of apoptosis, anddecreased matrix metalloproteinase and vascular endothelial growthfactor production...

IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial

...EM was well tolerated with evidence ofefficacy and induction of immune response in patients withprogressive metastatic melanoma. The data were presented by Merrick I. Ross, M.D., Professor ofSurgery, Chief, Melanoma Section, Department of Surgical Oncologyat The University of Texas M. D. Anderson Cancer Cente...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...entswith AML (over 60 years of age) given standard induction therapycontaining cytarabine and treated in the same time-period.Non-hematologic adverse events included myocardial infarction,dyspnea, hyperbilirubinemia, dehydration, syncope, headache, andhypokalemia. Phase 1 Study of Dacogen in Patients with Rel...

MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...ents with AML (over 60years of age) given standard induction therapy containingcytarabine and treated in the same time-period. Non-hematologicadverse events included myocardial infarction, dyspnea,hyperbilirubinemia, dehydration, syncope, headache, andhypokalemia. Phase 1 Study of Dacogen in Patients with Rel...

Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer

...l response or hadstable disease. Patients received induction chemotherapy with threecycles of anthracycline followed by three cycles of taxane, and were thenrandomly assigned to either the CAELYX or the observation arm. Theincidence of nausea/vomiting and alopecia were low and manageable;21 percent of patients...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

...y, or percent of planned doseintensity, during the induction and maintenance phases,respectively. Forty percent...alfa-2b at a dose of 6 ?g/kg/week for aneight week induction phase followed by 3 ?g/kg/wk (maintenancephase), for total treatment duration of 5 years. “W...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

...nt-associated antitumor immunity as measured bythe induction of T cell responses to the pancreaticcancer-associ...al, as well as the occurrence ofadverse events and induction of immune response. An earlier Phase 1 trial of GVAX immunotherapy for pancreaticcancer was conduct...

Introgen's Advexin Demonstrates Clinical Benefit in Inherited Cancer

... function includingsuppression of tumor growth and induction of tumor cell deathvalidating ADVEXIN's mechanisms of action. "This case study showcases and provides proof of the principlefor the therapeutic application of targeted ADVEXIN therapy intumors with p53 abnormalities that are among the most common an...

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

...ith cisplatin and fluorouracil isindicated for the induction treatment of patients with inoperablelocally advanced squamous cell carcinoma of the head and neck(SCCHN). Important safety information WARNING: Taxotere(R) treatment can cause serious, physicallylimiting, and potentially life-threatening side effe...

Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up

...on administered every6 weeks, following a standard induction regimen that requirestreatment at weeks 0, 2 and 6. Important Safety Information There are reports of serious infections, including tuberculosis(TB), sepsis and pneumonia. Some of these infections have beenfatal. Tell your doctor if you have had re...

UCB Presents Long-Term CImzia Data in Crohn's Disease

...every four weeks atstable doses of 400 mg, with an induction dose at weeks 0, 2 and 4.The patients represented ... enrolled in P3.Group B (99 patients) responded to induction therapy withCIMZIA(TM) in P2 at Weeks 0, 2 and 4, and were randomized toplacebo in P2 and then enrol...

New Analysis of Data Shows Treatment With Abbott's Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease

...m baseline) to HUMIRA during afour-week open-label induction phase were randomized to receiveeither HUMIRA or placebo. The co-primary endpoints evaluated themaintenance of clinical remission at weeks 26 and 56 for eachHUMIRA group compared to those on placebo. A significantly greaterpercentage of patients trea...

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

... Approved by the FDA on January 16, 2007, for the induction ofremission in patients with active, mild to moder...ontrolled trials that demonstrated efficacy forthe induction of remission in active, mild to moderate UC) andreceived LIALDA once daily (2.4g/day; n=171) or twic...

Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma

... of complete (CR) andpartial (PR) remissions after induction therapy. About MabThera MabThera is a therapeutic antibody that binds to a particularprotein - the CD20 antigen - on the surface of normal and malignantB-cells. It then recruits the body's natural defences to attack andkill the marked B-cells. Stem...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

...-line treatment for UC. LIALDA isindicated for the induction of remission in patients with active,mild to moder...Information for LIALDA Lialda is approved for the induction of remission in patientswith active, mild to moderate ulcerative colitis. Safety andefficacy of Lial...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

... in combination with intravenous steroidsand after induction with the immunosuppressant mitoxantrone; itscompatibility with other compounds may make it unique among thedisease modifying class of drugs and a treatment of interest forthe future study of combination therapies for MS," Metz added. About the Study...

Lux Biosciences' Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007

...he treatment ofuveitis." The poster describes the induction of EAU in rats, which werethen divided into three groups, designated preventative,therapeutic, and vehicle-control. Animals in the first two groupsreceived daily subcutaneous injections of either cyclosporine A(CsA) at 40 mg/kg or LX211 at 2.5 mg/kg,...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

... in combination with intravenous steroidsand after induction -more- GA Minocycline/Page 2 with the immunosup...tivity(p=0.0147). Treatment with COPAXONE(r) after induction withmitoxantrone remained safe and effective throughout the treatmentperiod. These new findings wer...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

...ultiple sclerosis (MS), whichdemonstrated that the induction treatment strategy was moreeffective than COPAXONE...tivity (p=0.0147). Treatment with COPAXONE(R)after induction with mitoxantrone remained safe and effectivethroughout the treatment period. These new findings wer...

Argos Therapeutics Presents Immunosuppression Data for Soluble CD83 at the American Society of Transplantation Congress 2007

...s that it plays an important functional role inthe induction of immune responses. Experimental data demonstratethat soluble CD83 can potently down-regulate immune responses,indicating that it can be developed to treat transplantationrejection and variety of autoimmune disorders. Importantly, datafrom animal mo...

New Report Illuminates Ampligen's Unique Mechanism of Action

...3 is essential for theactivities of dsRNAs for the induction of innate immunity. Unlikethe toxic Poly I:Poly C,... is directed towards theactivation of TLR-3 in the induction of innate immuneresponses. The closely allied compound, Poly I : Poly C, has been used inclinical t...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51

...e that SuperGen's novel compound,MP470, blocks the induction of Rad51 by anticancer platinum agents.MP470, in combination with carboplatin and paclitaxel in small celland non-small cell lung cancer lines, showed a significantimprovement in tumor response over the carboplatin/paclitaxeltreatments alone. A combi...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...roprietary nuclear export inhibitors (NEI) showing induction ofpotent, fast-acting and long-lasting anticancer activity with ahigh degree of tolerability in multiple human tumor xenograftcancer models. Kosan's NEIs are potent, specific inhibitors of CRM1, a highlyconserved, essential protein that exports key ...

Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting

...otinib sensitivity in wild type NSCLCcell lines by induction of profound apoptosis. This synergy wasalso shown in the nude mice xenografts but was not observed inepidermal growth factor (EGFR) mutant cell lines. "The data from this study are very promising and suggest thatcombining romidepsin with TKIs such a...

ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR

...lting in depletion of energysupply to the cell and induction of apoptosis (programmed celldeath). Increase in intra-cellular Reactive Oxygen Species enhancesthis effect on mitochondrial functions and consequently theactivation of the signal transduction pathway leading to apoptosis.In addition, ZIO-101 interru...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

...ed kinases,resulting in inhibition of cell growth, induction of apoptosis, anddecreased matrix metalloproteinase and vascular endothelial growthfactor production. In vitro, ERBITUX can mediate antibody-dependentcellular cytotoxicity (ADCC) against certain human tumor types.While the mechanism of ERBITUX' anti-...

Vion Presents Data on Cloretazine (VNP40101M) at the 100th Annual Meeting of the American Association of Cancer Research (AACR)

...rrelatewith response to Cloretazine(R) (VNP40101M) induction therapy" willbe presented on Monday, April 16 from 1 to 5 p.m. Sinceoverexpression of AGT has been associated with drug resistancepreclinically, these data were collected as part of a Phase IIclinical trial of Cloretazine(R) to assess whether pretrea...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

...ed kinases,resulting in inhibition of cell growth, induction of apoptosis, anddecreased matrix metalloproteinase and vascular endothelial growthfactor production. In vitro, ERBITUX can mediate antibody-dependentcellular cytotoxicity (ADCC) against certain human tumor types.While the mechanism of ERBITUX' anti-...

Nereus Pharmaceuticals to Present Data at the American Association for Cancer Research 2007 Annual Meeting

...or NPI-0052-induced apoptosis:pivotal role of PTEN induction and inhibition of Bcl-xL Eriko Suzuki, Michael Palladino, Benjamin Bonavida. David GeffenSchool of Medicine at UCLA, Los Angeles, CA, NereusPharmaceuticals, San Diego, CA #1454: A novel proteasome inhibitor, NPI-0052 is active inHodgkin and Mantle ...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

...ed kinases,resulting in inhibition of cell growth, induction of apoptosis, anddecreased matrix metalloproteinase and vascular endothelial growthfactor production. In vitro, ERBITUX can mediate antibody-dependentcellular cytotoxicity (ADCC) against certain human tumor types.While the mechanism of ERBITUX' anti-...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

...ed kinases,resulting in inhibition of cell growth, induction of apoptosis, anddecreased matrix metalloproteinase and vascular endothelial growthfactor production. In vitro, ERBITUX can mediate antibody-dependentcellular cytotoxicity (ADCC) against certain human tumor types.While the mechanism of ERBITUX' anti-...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis

...multiple sclerosis patientsresulted in the in vivo induction of CD8+ cytotoxic T-cells andCD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction ofanti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypicCD4+CD25+FoxP3 positive Tregs is ...

Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model

... that it is crucial to prevent the potential induction of cross-reactivity toward self-proteins, such as IL-2, post-vaccination in order to prevent potential long term autoimmune negative side-effects. About Mymetics Mymetics was founded in 1990 near Lyon, France and wasregistered as a US...

Study Presented at ACC Shows Treatment With ISIS 301012 Added to Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C Levels of Less Than 70 mg/dL

...ombination with statins, in which we expect to use induction dosesof 200 to 300 mg/week and define maintenance doses in the range of100 to 200 mg/week." ISIS 301012 Coadministered with Statins This randomized, double-blinded, placebo-controlled,dose-escalation study initially included five weeks of treatment...

Curecumin May Be an Effective Treatment for Lung Cancer

...olecular changes induced by curcumin leading tothe induction of apoptosis in human lung cancer cell lines -- A549and H1299... Curcumin inhibited the growth of both the cell linesin a concentration dependent manner... Curcumin induced apoptosisin both the lung cancer cell lines." Lung cancer is the leading c...

ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO

...501 in a human colon xenograft model -- Selective induction of necrotic cell death in cancer cells by(beta)-lapachone through activation of DNA damage responsepathway -- Evaluation of biomarkers for HGFR/c-Met inhibitor ARQ 197 ina human xenograft model -- Functional chemogenomics approach to identify check...